<?xml version='1.0' encoding='utf-8'?>
<document id="25446771"><sentence text="Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach."><entity charOffset="71-82" id="DDI-PubMed.25446771.s1.e0" text="Simvastatin" /><entity charOffset="109-125" id="DDI-PubMed.25446771.s1.e1" text="Simvastatin Acid" /><pair ddi="false" e1="DDI-PubMed.25446771.s1.e0" e2="DDI-PubMed.25446771.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s1.e0" e2="DDI-PubMed.25446771.s1.e1" /></sentence><sentence text="To develop a population physiologically-based pharmacokinetic (PBPK) model for simvastatin (SV) and its active metabolite, simvastatin acid (SVA), that allows extrapolation and prediction of their concentration profiles in liver (efficacy) and muscle (toxicity)"><entity charOffset="79-90" id="DDI-PubMed.25446771.s2.e0" text="simvastatin" /><entity charOffset="92-94" id="DDI-PubMed.25446771.s2.e1" text="SV" /><entity charOffset="123-139" id="DDI-PubMed.25446771.s2.e2" text="simvastatin acid" /><entity charOffset="141-144" id="DDI-PubMed.25446771.s2.e3" text="SVA" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e0" e2="DDI-PubMed.25446771.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e0" e2="DDI-PubMed.25446771.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e0" e2="DDI-PubMed.25446771.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e0" e2="DDI-PubMed.25446771.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e1" e2="DDI-PubMed.25446771.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e1" e2="DDI-PubMed.25446771.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e1" e2="DDI-PubMed.25446771.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e2" e2="DDI-PubMed.25446771.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25446771.s2.e2" e2="DDI-PubMed.25446771.s2.e3" /></sentence><sentence text="" /><sentence text="SV/SVA plasma concentrations (34 healthy volunteers) were simultaneously analysed with NONMEM 7"><entity charOffset="0-2" id="DDI-PubMed.25446771.s4.e0" text="SV" /><entity charOffset="3-5" id="DDI-PubMed.25446771.s4.e1" text="SV" /><pair ddi="false" e1="DDI-PubMed.25446771.s4.e0" e2="DDI-PubMed.25446771.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s4.e0" e2="DDI-PubMed.25446771.s4.e1" /></sentence><sentence text="2" /><sentence text=" The implemented mechanistic model has a complex compartmental structure allowing inter-conversion between SV and SVA in different tissues"><entity charOffset="107-108" id="DDI-PubMed.25446771.s6.e0" text="SV" /><entity charOffset="114-115" id="DDI-PubMed.25446771.s6.e1" text="SV" /><pair ddi="false" e1="DDI-PubMed.25446771.s6.e0" e2="DDI-PubMed.25446771.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s6.e0" e2="DDI-PubMed.25446771.s6.e1" /></sentence><sentence text=" Prior information for model parameters was extracted from different sources to construct appropriate prior distributions that support parameter estimation" /><sentence text=" The model was employed to provide predictions regarding the effects of a range of clinically important conditions on the SV and SVA disposition"><entity charOffset="122-124" id="DDI-PubMed.25446771.s8.e0" text="SV" /><entity charOffset="129-130" id="DDI-PubMed.25446771.s8.e1" text="SV" /><pair ddi="false" e1="DDI-PubMed.25446771.s8.e0" e2="DDI-PubMed.25446771.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s8.e0" e2="DDI-PubMed.25446771.s8.e1" /></sentence><sentence text="" /><sentence text="The developed model offered a very good description of the available plasma SV/SVA data"><entity charOffset="76-77" id="DDI-PubMed.25446771.s10.e0" text="SV" /><entity charOffset="79-80" id="DDI-PubMed.25446771.s10.e1" text="SV" /><pair ddi="false" e1="DDI-PubMed.25446771.s10.e0" e2="DDI-PubMed.25446771.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s10.e0" e2="DDI-PubMed.25446771.s10.e1" /></sentence><sentence text=" It was also able to describe previously observed effects of an OATP1B1 polymorphism (c" /><sentence text="521 T &gt; C) and a range of drug-drug interactions (CYP inhibition) on SV/SVA plasma concentrations"><entity charOffset="69-70" id="DDI-PubMed.25446771.s12.e0" text="SV" /><entity charOffset="72-73" id="DDI-PubMed.25446771.s12.e1" text="SV" /><pair ddi="false" e1="DDI-PubMed.25446771.s12.e0" e2="DDI-PubMed.25446771.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s12.e0" e2="DDI-PubMed.25446771.s12.e1" /></sentence><sentence text=" The predicted SV/SVA liver and muscle tissue concentrations were in agreement with the clinically observed efficacy and toxicity outcomes of the investigated conditions"><entity charOffset="15-17" id="DDI-PubMed.25446771.s13.e0" text="SV" /><entity charOffset="18-19" id="DDI-PubMed.25446771.s13.e1" text="SV" /><pair ddi="false" e1="DDI-PubMed.25446771.s13.e0" e2="DDI-PubMed.25446771.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s13.e0" e2="DDI-PubMed.25446771.s13.e1" /></sentence><sentence text="" /><sentence text="A mechanistically sound SV/SVA population model with clinical applications (e"><entity charOffset="24-25" id="DDI-PubMed.25446771.s15.e0" text="SV" /><entity charOffset="27-28" id="DDI-PubMed.25446771.s15.e1" text="SV" /><pair ddi="false" e1="DDI-PubMed.25446771.s15.e0" e2="DDI-PubMed.25446771.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25446771.s15.e0" e2="DDI-PubMed.25446771.s15.e1" /></sentence><sentence text="g" /><sentence text=", assessment of drug-drug interaction and myopathy risk) was developed, illustrating the advantages of an integrated population PBPK approach" /><sentence text="" /></document>